Quince Therapeutics (QNCX) to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia Jul 24, 2023 07:04AM
Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity Jul 24, 2023 07:00AM